STOCK TITAN

Aprea reports 1 confirmed APR-1051 partial response

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. reported interim results from its ongoing Phase 1 ACESOT-1051 trial of investigational APR-1051, an oral selective WEE1 inhibitor. As of November 1, 2026, 56 patients had received APR-1051 across dose levels. The dataset included one confirmed and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers, plus five patients with stable disease lasting more than four months; the confirmed responder had been on treatment for more than 10 months at cutoff.

Aprea said pharmacodynamic data showed WEE1 target engagement across multiple doses and pharmacokinetics supported once-daily administration. It plans to enroll at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer; completion of dose escalation and backfill expansion enrollment is expected in the second quarter of 2027. The trial is expanding to more than 10 sites from nine active sites.

Filing Explained

The filing says ACESOT-1051’s Part 1 dose escalation and backfill are ongoing, with capacity for up to 110 patients; its design then includes a Part 2 dose-selection stage for up to 80 patients randomized between two doses to determine the recommended Phase 2 dose.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Patients treated 56 patients Across all dose levels as of November 1, 2026
Confirmed partial responses 1 response In a patient with PPP2R1A-mutated uterine cancer; on treatment for more than 10 months at the November 1, 2026 cutoff
Unconfirmed partial responses 1 response In a patient with PPP2R1A-mutated uterine cancer
Stable disease 5 patients Stable disease lasting more than four months
Planned focused-cohort enrollment At least 50 patients Uterine serous carcinoma or cyclin E-overexpressing, platinum-resistant ovarian cancer
Part 1 trial enrollment Up to 110 patients Dose escalation and backfill expansion
Part 2 trial enrollment Up to 80 patients Dose-selection optimization; randomized 1:1 to two selected doses
Clinical sites More than 10 sites Trial expansion from nine active sites previously disclosed
RECIST 1.1 medical
"RECIST 1.1 partial response"
RECIST 1.1 is a standardized set of rules used in cancer clinical trials to measure how solid tumors respond to treatment by tracking changes in size on medical scans. Think of it as a consistent ruler and scorecard that tells doctors and regulators whether a drug is shrinking tumors, keeping them stable, or allowing them to grow. Investors care because RECIST-based results are common primary endpoints that influence regulatory decisions, trial success, and a therapy’s commercial prospects.
pharmacodynamic medical
"Pharmacodynamic evidence of WEE1 target engagement"
Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.
Bayesian optimal interval (BOIN) design technical
"a Bayesian optimal interval (BOIN) design"
dose-limiting toxicities medical
"characterize safety and dose-limiting toxicities"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
immunohistochemistry (IHC) assay medical
"develop an immunohistochemistry (IHC) assay"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What interim activity did APRE report for APR-1051?

The interim dataset included one confirmed and one unconfirmed partial response in patients with PPP2R1A-mutated uterine cancers, plus five patients with stable disease lasting more than four months. The confirmed responder had been on treatment for more than 10 months at the November 1, 2026 cutoff.

How many patients have received APR-1051 in APRE's trial?

56 patients had received APR-1051 across all dose levels as of November 1, 2026.

How is APRE's ACESOT-1051 trial designed?

Part 1 includes dose escalation and backfill expansion of up to 110 patients. Part 2 is a dose-selection optimization stage of up to 80 patients, randomized 1:1 to two selected doses. APR-1051 is administered once daily in 28-day cycles.

What assay is APRE developing for its planned ovarian cancer cohort?

Aprea is working with a diagnostics partner to develop an immunohistochemistry assay for cyclin E overexpression to support patient identification and enrollment in cyclin E-overexpressing, platinum-resistant ovarian cancer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001781983 0001781983 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

November 20, 2026

Date of Report (Date of earliest event reported)

 

 

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-39069 84-2246769
(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     

3805 Old Easton Road

Doylestown, PA

(Address of principal executive offices)

 

18902

(Zip Code)

       

Registrant's telephone number, including area code: (215) 948-4119

 

(Former name or former address, if changed since last report): Not applicable 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   

Name of each exchange on

which registered

Common stock, par value $0.001 per share   APRE   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On November 20, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

In addition, on November 20, 2026, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
​ ​ ​ Description
99.1   Press release dated November 20, 2026.
99.2   Corporate Presentation (November 2026).
104   Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Aprea Therapeutics, Inc.
   
Dated: November 20, 2026 By: /s/ Oren Gilad
  Name: Oren Gilad, Ph.D.
  Title: President and Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

 

Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development

 

Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration

 

Planned expansion into focused cohorts in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, where WEE1 inhibition may be most therapeutically relevant

 

DOYLESTOWN, PA, November 20, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center, the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels. The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027.

 

Updated ACESOT-1051 findings

 

The presentation, “Interim Results From the First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051),” includes the following findings:

 

·Clinical activity and durability: Out of the 56 patients who enrolled in this dose escalation trial (including those patients treated at doses believed to be subtherapeutic), 43 are evaluable for response. Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses, one confirmed and one unconfirmed. The confirmed response, in a patient with uterine carcinosarcoma treated at 220 mg, was ongoing with treatment beyond 10 months at the time of data cutoff. Sixteen patients had a best overall response of stable disease, five of which had a duration of 4 months or longer. Thirteen patients were still awaiting their initial on-treatment imaging studies at the time of data cutoff.

 

·WEE1 target engagement: Pharmacodynamic data (PD) from paired skin punch biopsies were stained by IHC for phosphorylation of CDK1-Y15, an established PD marker of WEE1 target engagement. Reductions of at least 50% in pCDK1-Y15 from baseline were observed in 21 of 25 evaluable patients (84%) across multiple dose levels.

 

 

 

·Initial Safety and tolerability: One dose-limiting toxicity (DLT) was observed among 56 treated patients. The DLT was elevation of AST and ALT without elevation in bilirubin in blood tests in a patient with known liver metastases treated at the 50 mg dose level. Grade 3/4 neutrophil count decrease was reported in 4 patients (7%) (1 Grade 3, 3 Grade 4, one of which was serious) all at the 300 mg dose level, with no reported cases of febrile neutropenia. Two patients (4%) experienced Grade 3 pneumonitis, both reported as serious. Other Grade ≥3 treatment-related adverse events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea (2%). The most common all grade treatment-related adverse events were nausea (41%), fatigue (25%), diarrhea (14%) and vomiting (14%).

 

·Pharmacokinetics: APR-1051 exposure increased with once-daily dosing through 300 mg, with an approximately 18-hour median half-life supporting once-daily dosing. Dose escalation has been modified to include 250 mg and 350 mg dose levels, and Part 1 now provides for up to 110 patients; previously disclosed dose levels of 400 mg and 500 mg are under evaluation.

 

“These interim results reinforce our focus on advancing APR-1051 in biomarker selected cancers,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target engagement and pharmacokinetics compatible with continuous once-daily dosing. Our strategy is to transition from a broad, biomarker-enriched Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051. Our goal is to evaluate whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet medical need.”

 

Expanded enrollment focused on biologically selected cancers

 

Aprea is refining enrollment to evaluate APR-1051 in populations that may be particularly sensitive to WEE1 inhibition. The Company is working with a diagnostics partner to develop an immunohistochemistry (IHC) assay for cyclin E overexpression, to support patient identification and enrollment of patients with cyclin E-overexpressing PROC. The Company is also expanding the trial to more than 10 clinical sites, from the nine active sites previously disclosed. This effort complements continued evaluation of tumors with CCNE1, CCNE2 or FBXW7 alterations, while an emerging clinical activity signal in PPP2R1A-mutated uterine cancers provides an additional area for evaluation as enrollment expands.

 

“Patients with advanced uterine and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies,” said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. “The observed target engagement and prolonged treatment duration in a patient with a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients. Expanding enrollment in biologically selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability. These data will be important for optimizing dose selection and informing subsequent development.”

 

ACESOT-1051 Trial Design

 

ACESOT-1051 is a multicenter, open-label Phase 1 study evaluating oral, single-agent APR-1051 administered once daily in 28-day cycles. Part 1 includes dose escalation and backfill expansion of up to 110 patients, using accelerated titration at lower dose levels followed by a Bayesian optimal interval (BOIN) design. Backfill enrollment allows additional patients to be evaluated at dose levels that have cleared safety review. Part 2 is a dose selection optimization stage of up to 80 patients, who will be randomized 1:1 to two selected doses to determine the recommended Phase 2 dose (RP2D).

 

 

 

 

The primary objectives are to characterize safety and dose-limiting toxicities, determine the maximum tolerated or maximum administered dose, and establish the RP2D. Secondary objectives include pharmacokinetics and preliminary antitumor activity assessed using Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate Cancer Working Group 3 (PCWG3) criteria, as applicable.

 

For more information on ACESOT-1051, refer to ClinicalTrials.gov identifier NCT06260514.

 

About APR-1051

 

APR-1051 is an investigational, orally bioavailable, selective small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond to DNA damage. APR-1051 was designed to minimize off-target inhibition of the PLK family of kinases, with the goal of improving its therapeutic profile. Its potential differentiation remains under clinical evaluation.

 

About Aprea

 

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pursuing an approach to treating cancer that seeks to exploit vulnerabilities associated with cancer cell mutations. This approach is designed to kill tumor cells while minimizing the effect on normal, healthy cells. Aprea believes its technology has potential applications across multiple cancer types, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead program is APR-1051, an oral, small molecule inhibitor of WEE1 kinase, currently in a Phase 1 clinical trial. The Company’s second clinical-stage product candidate, ATRN-119, is a small molecule ATR inhibitor for which the Company has completed a Phase 1 dose-escalation study and is exploring combination approaches. For more information, please visit the Company’s website at www.aprea.com.

 

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

 

 

 

Forward-Looking Statements

 

Certain information contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, related to our study analyses, clinical trials, regulatory submissions, development plans and projected cash position. We may, in some cases, use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management, and involve risks, potential changes in circumstances, assumptions and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned product candidates, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, projected cash runway, plans and objectives for future operations, the timing, progress, enrollment and completion of our ongoing and planned clinical trials, the timing of expected clinical data updates and medical meeting presentations, the potential expansion of ACESOT-1051, the planned addition of clinical sites and dose levels, the development of a companion IHC assay, the potential development of APR-1051 in single-agent and combination settings, the potential further development of ATRN-119, the scope and duration of our intellectual property protection, and the potential advancement of our early-stage programs. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing and anticipated clinical trials for our current product candidates, including the timing of initiation, pace of enrollment and completion of trials, our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses, our need for substantial additional funding, which may not be available on acceptable terms or at all, the receipt and timing of interim or preliminary results, which are not necessarily indicative of final results and have not been fully source verified, the occurrence of serious or unexpected adverse events, including pneumonitis and neutropenia, that may require dose modifications or affect further development, our understanding of product candidate mechanisms of action and interpretation of preclinical and early clinical results from our clinical development programs, our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to successfully develop and validate a diagnostic assay with third parties, the timing and outcome of regulatory interactions, our ability to regain and maintain compliance with The Nasdaq Stock Market continued listing requirements, and the other risks, uncertainties and factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

 

Investor Contact:

 

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

 

Media Contact:

 

Sean Naughton Ph.D.
Russo Partners, LLC
sean.naughton@russopartnersllc.com

 

 

 

Exhibit 99.2 

 

GRAPHIC

1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers November 2026

GRAPHIC

2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, related to our study analyses, clinical trials, regulatory submissions, development plans and projected cash position. We may, in some cases, use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management, and involve risks, potential changes in circumstances, assumptions and uncertainties. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned product candidates, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, projected cash runway, plans and objectives for future operations, the timing, progress, enrollment and completion of our ongoing and planned clinical trials, the timing of expected clinical data updates and medical meeting presentations, the potential expansion of ACESOT-1051, the planned addition of clinical sites and dose levels, the development of a companion IHC assay, the potential development of APR-1051 in single-agent and combination settings, the potential further development of ATRN-119, the scope and duration of our intellectual property protection, and the potential advancement of our early-stage programs. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing and anticipated clinical trials for our current product candidates, including the timing of initiation, pace of enrollment and completion of trials, our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses, our need for substantial additional funding, which may not be available on acceptable terms or at all, the receipt and timing of interim or preliminary results, which are not necessarily indicative of final results and have not been fully source verified, the occurrence of serious or unexpected adverse events, including pneumonitis and neutropenia, that may require dose modifications or affect further development, our understanding of product candidate mechanisms of action and interpretation of preclinical and early clinical results from our clinical development programs, our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to successfully develop and validate a diagnostic assay with third parties, the timing and outcome of regulatory interactions, our ability to regain and maintain compliance with The Nasdaq Stock Market continued listing requirements, and the other risks, uncertainties and factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to update such forward-looking statements for any reason, except as required by law. This presentation may not be reproduced, forwarded to any person or published, in whole or in part. APR-1051 and ATRN-119 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration or any other regulatory authority.

GRAPHIC

3 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

GRAPHIC

4 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE) One Critical Pathway - Multiple Targets 1. Ngoi N, et al. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer. (2021); 7(10):930-957 Precision Medicine Synthetic Lethality Aprea DYRK1 Target Trends in Cancer 1 Positioned at the forefront of synthetic lethality and precision medicine Transition from broad, toxic chemotherapy to potentially safer, precision-guided targeted therapies Targeted Oncology Develop highly selective cancer therapies that exploit tumor-specific mutations to maximize cancer cell killing while sparing healthy tissue Precision-Driven Development All programs are designed to address significant unmet medical needs across genetically defined cancer populations Pipeline with Clinical Momentum Preliminary signals of monotherapy activity observed in ongoing Phase 1 trial Early Clinical Proof-of-Concept

GRAPHIC

5 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 2025 2026 2027 2028 H2 H1 H2 H1 H2 H1 H2 Financing WEE1 APR-1051 ATR ATRN-119 (mosipasertib) DYRK1 Inhibitor Robust DDR Development Pipeline and Corporate Milestones 2025-2028 Accomplished and anticipated milestones DNA Damage Response (DDR), Uterine Serous Carcinoma (USC), Platinum-resistant Ovarian Cancer (PROC) *FPI contingent upon execution of a research collaboration or partnering agreement; study initiation is expected to be externally supported without use of current company resources. RP2D for QD dosing ACESOT-1051: Phase 1 – Monotherapy Dose Escalation Complete Dose Escalation and Backfill Enrollment ACESOT-1051: Monotherapy Dose Selection Optimization Safety & Efficacy Data Safety & Efficacy Data Phase 1/2a : Combinations to Expand Therapeutic Potential Open Backfill Cohorts Lead Optimization ABOYA-119: Phase 1/2a Dose Escalation: QD/BID Interim Safety & Efficacy Presentation FPI* Lead Identification $30 Million Raise Enriched for USC and Cyclin E PROC Combinations in HPV+ Head and Neck Cancer and Colorectal Cancer

GRAPHIC

6 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Board of Directors Richard Peters, MD, PhD Chairman of the Board Oren Gilad, PhD President and CEO Jean-Pierre Bizzari, MD Director Marc Duey Director Michael Grissinger Director Gabriela Gruia, MD Director John Henneman Director Rifat Pamukcu, MD Director Bernd R. Seizinger, MD, PhD Director Oren Gilad, PhD President and CEO John P. Hamill SVP and CFO Eugene Kennedy, MD Chief Medical Advisor Ze’ev Weiss, CPA, BSc Chief Business Advisor Mike Carleton, PhD Translational Medicine Advisor Brian Wiley SVP, Corporate Strategy

GRAPHIC

7 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 7 WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept

GRAPHIC

8 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved WEE1 Has Emerged as a Therapeutic Target of Significant Industry Interest 1. Zentalis Corporate Presentation, April 2026 2. Debio 0123-101, A Phase 1 Trial of Debio 0123 In Combination With Carboplatin In Advanced Solid Tumors: Safety, Pharmacokinetic, And Preliminary Antitumor Activity Data, Poster ASCO 2023 3. Abstract 3120, ASCO 2024 4. Poster CT022, AACR 2026 Clinically validated, prior WEE1 inhibitors have been challenged by narrow therapeutic windows Aprea is applying key insights to advance APR-1051 as a potentially best-in-class WEE1 inhibitor Program Clinical Limitations Strategic Outcome What It Signals Adavosertib (AstraZeneca) Hematologic & GI toxicity limited dose intensity Terminated further clinical development Returned by AstraZeneca to Merck & Co. Biology works, narrow therapeutic window Azenosertib (Zentalis) Continuous dosing not tolerated1 TRAEs leading to dose reductions, interruptions and discontinuation Biology works Debio 0123 (Debiopharm) QT prolongation liability at high doses2 Limited single-agent activity – no responses up to MTD3; activity seen in combination with PKMYT1 inhibitor4 Potential future as combination agent No head-to-head studies have been conducted. Trial information is based on publicly available data and should be interpreted cautiously Program Engineered Profile Strategic Outcome What It Signals APR-1051 (Aprea Therapeutics) Structurally differentiated, highly potent, limited off-target inhibition Preliminary signals of monotherapy activity Potential to expand therapeutic window TRAEs – Treatment related adverse events

GRAPHIC

9 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT-1051: Phase 1 Study Design Multi-center, open-label Phase 1 single-agent dose escalation and dose selection optimization Part 1 Dose escalation up to 110 patients RP2D Oral single-agent APR-1051 will be administered once-daily for 28-day cycles Objectives Primary: Safety, DLT, MTD/MAD, RP2D Secondary: Pharmacokinetics, Antitumor activity (RECIST/PCWG3) Exploratory: Pharmacodynamics = cleared Accelerated titration; 1-6 patients per dose level BOIN design; 3-12 patients per dose level Part 2 Dose selection optimization Up to 80 patients Selected dose 2 Selected dose 1 1:1 randomization R Dose level 1-3 10 – 30 mg Dose level 4 50 mg Dose level 5 70 mg Dose level 6 100 mg Dose level 7 150 mg Dose level 8 220 mg Dose level 9 250mg Confirmed PR Observed First uPR Observed Select 2 dose levels Eligible patients ≥ 18 yo with advanced solid tumor harboring cancer-associated gene alterations o USC regardless biomarker status o Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) o CCNE1, CCNE2, FBXW7 or PPP2R1A o HPV+ oropharyngeal squamous cell carcinoma, cervical, vaginal, or vulvar carcinoma o KRAS-GLY12/GLY13 & TP53 colorectal cancer = currently enrolling Backfill Backfill Backfill Dose level 10 300mg Dose level 11 350mg Backfill

GRAPHIC

10 © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051 Summary of Duration of Treatment (n=56 for all dose levels) Data Cutoff: November 1, 2026

GRAPHIC

11 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Treatment-related AEs in Patients Treated with APR-1051 (N=56) Not all data source verified Data Cutoff: November 1, 2026 MedDRA Preferred Term APR-1051 all dose levels (N = 56) TRAEa , n (%) All Grades Grade ≥ 3b Nausea 23 (41) 0 (0) Fatigue 14 (25) 3 (5) Diarrhea 8 (14) 1 (2) Vomiting 8 (14) 0 (0) Neutrophil count decrease 5 (9) 4 (7)d Anemia 4 (7) 0 (0) Platelet count decrease 4 (7) 0 (0) Dehydration 3 (5) 0 (0) ALT increase 2 (4) 2 (4)c Anorexia 2 (4) 0 (0) MedDRA Preferred Term APR-1051 all dose levels (N = 56) TRAEa , n (%) All Grades Grade ≥ 3b AST increase 2 (4) 2 (4)c Constipation 2 (4) 0 (0) Creatinine increase 2 (4) 0 (0) Dysgeusia 2 (4) 0 (0) Dyspnea 2 (4) 1 (2) GERD 2 (4) 0 (0) Headache 2 (4) 0 (0) Lymphocyte count decrease 2 (4) 2 (4) Pneumonitis 2 (4) 2 (4)e Other* 12 (21) 0 (0) MedDRA Preferred Term APR-1051 all dose levels (n = 56) *TRAEs that were reported in 1 (2%) patient each: abdominal pain, blood bilirubin increase, blurred vision, dizziness, dyspepsia, eczema, fall, GI disorder, hot flashes, hypokalemia, hypomagnesemia, insomnia, proteinuria, urticaria, weight loss a A patient may have more than one AE and/or have the same AE more than once. b Grade 3 unless otherwise indicated based on CTCAE v5.0. c In one patient, Grade 3 ALT and AST increase were a DLT. d Three patients had Grade 4 neutrophil count decrease, one event was serious. e Both events were serious • 1 DLT observed: AST / ALT increase without bilirubin increase at 50mg in patient w/ liver metastases • Low incidence (7%) of Grade 3/4 neutropenia with no febrile neutropenia • Low incidence of Grade 3+ gastrointestinal toxicity – diarrhea (2%) • TRAEs were primarily Grade 1 and 2 gastrointestinal events and fatigue

GRAPHIC

12 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Inhibition of pCDK1-Y15 is a PD Marker for WEE1 Inhibition APR-1051 suppresses phosphorylation of CDK1-Y15 across multiple doses • pCDK1-Y15 suppression is the primary confirmatory biomarker of WEE1 target engagement and dose-justification for APR-1051 • Paired skin punch biopsies were stained with IHC for pCDK1-Y15 • Consistent and substantial pCDK1-Y15 suppression observed in most patients

GRAPHIC

13 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Confirmed Partial Response in Patient 01-011 220mg QD – Currently on treatment Demographics: 63-year-old Black Female Site: MD Anderson Cancer Center Diagnosis: Uterine carcinosarcoma Key Mutations: PPP2R1A Treatment History (4 prior lines) • Line 1: Carboplatin + Paclitaxel → 126 days, PD • Line 2: Doxorubicin → 56 days, PD • Line 3: Topotecan → 70 days, PD • Line 4: Pembrolizumab + Lenvatinib → 5months, PD APR-1051 – Treatment Outcome • C1D1: Dec 18, 2025 • Current Status: On treatment 320 days (C12D10) November 1, 2026 • Best Response: Confirmed Partial Response (PR) • PR (-50%) at first assessment Feb 10, 2026 • Confirmed PR with additional -9.5% reduction from C3D1 Mar 10, 2026; scans continue to show approximately 50% tumor reduction. • Tumor marker: CA-125 reduction from BL 362.4 U/mL to C3D1 46.8 U/mL ; 40.2 U/mL March 11, 2026; 53 U/ml April 08, 2026; 80 U/ml June 02, 2026; 103 U/ml July 28, 2026; 122 U/ml September 22, 2026 • Adverse Events: All AEs reported to date Grade 1 only

GRAPHIC

14 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Disease Control Observed in Early Patient Outcomes APR-1051 shows preliminary evidence of disease control in rectal cancer with mutated FBXW7 100 mg Cohort Case Report Patient: 86-year-old Asian Female Diagnosis: Rectal Cancer Key Mutations: FBXW7 (Drives Cyclin E accumulation and overexpression) Treatment History: 5 prior lines - heavily pretreated • Line 1: Capecitabine/oxaliplatin → 191 days, PD • Line 2: Capecitabine/oxaliplatin/bevacizumab → 45 days, PD • Line 3: FOLFIRI + bevacizumab → 43 days, PD • Line 4: Local XRT (lung mets) → 12 days, not evaluable • Line 5: Tretinoin/bevacizumab/Tecentriq (ATRT trial) → 50 days, PD APR-1051 Activity: • Current Status: Consent withdrawn after 178 days • Best Response: SD at third scan (-15% tumor response) Notes: Durable SD maintained 181 days in a heavily pretreated 86-year-old patient; well tolerated with minimal toxicity. FBXW7 mutation may be relevant to response Stable disease maintained for 178 days in patient with FBXW7 mutation (100 mg QD) (elected to stop study participation)

GRAPHIC

15 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 70 mg Cohort Case Report Disease Control Observed in Early Patient Outcomes Patient: 62-year-old White Male Diagnosis: HPV+ Oropharyngeal Squamous Cell Carcinoma (base of tongue) Key Mutations: P16+ Treatment History: 3 prior lines • Line 1: Concomitant cisplatin/XRT → 49 days, PD • Line 2: Pembrolizumab→ 84 days, PD • Line 3: Paclitaxel/carboplatin → 184 days, PD APR-1051 Activity • Current Status: PD after 223 days of SD treatment • Best Response: SD at first scan (-5% tumor response) Notes: Stable disease maintained for 223 days. APR-1051 shows preliminary evidence of disease control in HPV+ head and neck cancer Stable disease maintained for 223 days in patient 01-005 HPV+ head and neck cancer (70 mg QD) (PD)

GRAPHIC

16 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Development Strategy: Biomarker Defined Registration Path *Data as of November 1, 2026 and are preliminary from an ongoing dose-escalation study. Responses and stable disease defined by RECIST 1.1 on first on-treatment scan require confirmation in additional patients and may change as follow-up matures. Safety and efficacy outcomes may vary by dose, schedule, and patient characteristics. Preliminary signals of monotherapy activity across cohorts in genomically defined tumors including uterine cancer, endometrial cancer, CRC and HNSCC • Responses across dose levels support a biomarker enriched expansion path • Activity beyond endometrial cancer supports additional biomarker-defined cohorts Clinical Activity by Indication and Biomarker Path to Registrational Cohort 1 Expand USC and CycE-PROC Add additional cohorts • CRC FBXW7-mutated • HPV+ cancers • PPP2R1A mutated 2 Confirm durability, consistency of response and safety 3 Indication Biomarker / Altered Genes Clinical Activity in ACESOT-1051* Uterine/ Endometrial Cancer PPP2R1A 2 PR CCNE1 4 SD overexpressed TP53 CRC KRAS & TP53 7 SD FBXW7 HNSCC HPV+ 1 SD Other TP53 FBXW7, other 4 SD Not all data source verified

GRAPHIC

17 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 17 APR-1051: Potentially Differentiated WEE1 Inhibitor

GRAPHIC

18 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Structurally differentiated: high potency, limited off-target inhibition design compared to other molecules AstraZeneca Adavosertib (AZD-1775) Zentalis Azenosertib (ZN-c3) Aprea APR-1051 Undisclosed APR-1051 is based on a different molecular structure than AZD-1775 and ZN-c3 (not an analogue) No head-to-head clinical studies have been conducted.

GRAPHIC

19 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Pharmacokinetics of Adavosertib (AZD1775) and Azenosertib (ZN-c3) Takebe et al., Clinical Cancer Research 2021 Zentalis Pharmaceuticals, Inc. FORM 10-K For the fiscal year ended December 31, 2021 • Median Tmax: 1 to 4 hours (fasted) • Cmax and AUC0-24h: Highly variable; dose-dependent increase up to 300 mg, with apparent plateau at higher doses • RP2D (300 mg QD): Mean steady-state AUC0-24h of 11,000 ng·h/mL (CV 52%) Adavosertib PK Azenosertib PK Zentalis Pharmaceuticals, Inc. Corporate Presentation November 2021

GRAPHIC

20 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PK Data Support Once-daily Dosing of APR-1051 18-hour median half-life, limited peak-to-average concentration difference • Exposure increases with once-daily dosing through 300 mg • Median half-life of ~18 hours and median Tmax of 4 hours after the first dose • Accumulation with once-daily dosing is ~2.3-fold based on AUC Not all data source verified

GRAPHIC

21 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Potent inhibitor of WEE1 Does not substantially inhibit structurally and functionally related PLK1, PLK2 or PLK3 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK1 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK2 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK3 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 ZN-c3 = 92.1 nM APR-1051 = 15,900 nM PLK1 Inhibition IC50 >150-fold difference ZN-c3 = 32.0 nM APR-1051 = 1,800 nM PLK2 Inhibition IC50 >50-fold difference ZN-c3 = 52.2 nM APR-1051 = 31,600 nM PLK3 Inhibition IC50 >600-fold difference Important difference in off-target inhibition between APR-1051 and ZN-c3 On 1 -target WEE1 potency1 ZN-c3 = 2.9 nM APR-1051 = 1.6 nM WEE1 Inhibition IC50 similar to ZN-c3 WEE1 IC50 Determination % Activity Log10 [conc] (M) 1 AACR-NCI-EORTC Meeting, Poster B323, 2024 Data from exploratory in-vitro studies. No head-to-head clinical studies have been conducted. APR-1051 specificity for WEE1 opens potential for greater therapeutic window

GRAPHIC

22 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors1 Minimal PLK1 co-inhibition enhances therapeutic window for APR-1051 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM 1 µM Phos-H2AX Control (MCM3) NT Phos-CDK1 APR-1051 75 nM GSK-PLKi Control (MCM3) 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM NT 1 µM Phos-H2AX 400 nM BI-PLKi APR-1051 Phos-CDK1 PLK inhibitor, BI-2536, interferes with the effects of APR-1051 in OVCAR-3 cells 1 AACR-NCI-EORTC Meeting, Poster B323, 2024 Data from exploratory in-vitro studies Evidence of DNA damage allowed by WEE1 inhibition. PLK1 reduces functional potency of WEE1 inhibition. PLK inhibitor, GSK-461364, interferes with the effects of APR-1051 in OVCAR-3 cells Inhibition of PLK1 reduces efficacy of WEE1 inhibition. Results in requiring higher doses of WEE1 inhibitors and introduces PLK1 related toxicity.

GRAPHIC

23 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Studies Show PLK1 Suppression is Associated with Sepsis-Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis-induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects intestinal barrier function in sepsis: A translational research, Cao et al, Cytokine (2023). 3 PLK1 protects intestinal barrier function in sepsis: A translational research, Cao et al, Molecular Medicine (2022). 4 LncRNA DANCR improves the dysfunction of the intestinal barrier and alleviates epithelial injury by targeting the miR‐1306‐5p/PLK1 axis in sepsis, Wang et al., Cell Biology International (2021).

GRAPHIC

24 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer* UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post Treatment Tumor Volume (mm3 ) Days since start of xenograft mEER tumor cells Tumor Volume (mm3 ) Days since start of xenograft APR-1051 Showed Preclinical Activity in Combination with Chemo, IO and ATRi Across Multiple Cancer Models * Data on file. Start of treatment Start of treatment ** P<0.0001 * P=0.0067 ** ** * Chemotherapy Immuno-oncology DDR combination APR-1051 suggests synergistic potential preclinically with standard oncology agents

GRAPHIC

25 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Ongoing Trial Progress Further focus on patient populations likely to respond to WEE1 inhibition • PPP2R1A mutated uterine cancers represent an emerging clinical efficacy signal of an unmet clinical need • Continued focus on genomic biomarkers including CCNE1, CCCNE2, FBXW7 • Working with diagnostics partner to develop IHC for Cyclin E overexpression underway, allowing for enrollment of patients with Cyclin E overexpressing platinum-resistant ovarian cancer (PROC) • Trial intends to enroll 50+ patients with USC or Cyclin E overexpressing PROC • Ongoing expansion of clinical trial to 10+ trial sites to complete dose escalation and backfill expansion enrollment by end of Q2 2027

GRAPHIC

26 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Clinically validated target • WEE1 inhibitors have shown promising activity in genomically defined tumors • Competitor programs constrained by low therapeutic window APR-1051 clinical highlights • Preliminary clinical single-agent proof-of-concept observed in heavily pretreated patients with advanced solid tumors • Potentially favorable safety profile at active dose levels1 • Potentially favorable PK1 , including an approximately 18-hour half-life and continuous once-daily administration • Robust WEE1 target engagement: consistent suppression of pCDK1-Y15 across multiple dose levels APR-1051 preclinical differentiation and potentially best-in-class opportunity • Novel structure with high potency, limited off-target inhibition design • Minimal PLK1 inhibition may enhance therapeutic window • Potential for synergy demonstrated in combination with standard oncology agents APR-1051 WEE1 Summary A next-generation WEE1i with the potential to deliver meaningful clinical benefit and durable value 2 3 1 1 No head-to-head clinical studies have been conducted.

GRAPHIC

27 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 27 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights

GRAPHIC

28 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1 Ataxia Telangiectasia and Rad3-Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 • Patents granted in AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, HK. • 1.1: Issued on May 30, 2017 as U.S. Patent 9,663,535; 1.2: Issued on May 29, 2018 as U.S. Patent 9,981,989; 1.3: Issued on Feb. 5, 2019 as U.S. Patent 10,196,405 Family 2 ATR Inhibitors and Methods of Use • Carboxylic acid-containing macrocyclic ATR inhibitors, and prodrugs; methods of using these inhibitors to treat various cancers; filed on Apr. 12, 2017 • Issued on May 28th, 2019 as U.S. Patent 10,301,324 Family 3 ATR Inhibitor Pharmaceutical Composition and Methods • International application filed on Apr. 14, 2023 • Pharmaceutical formulation and composition of our lead ATR inhibitor in the clinic • Patent granted in JP and EA; Applications pending US, AU, BR, CA, CN, EP, HK, IL, IN, KR, MX, NZ, PH, SG, ZA Family 4 WEE1 Inhibitor Pharmaceutical Compositions and Methods • International Application filed on Jun. 3, 2022 • Composition of our lead WEE1 inhibitor compounds • Patent granted in AU; Applications pending in US, AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, ZA Family 5 Methods of Treating Cancer • Clinical methods of treating advanced solid cancer tumors using lead ATR inhibitor • International application filed on Sept. 19, 2025 Family 6 Macrocyclic DYRK1A-B Inhibitors and Methods of their Preparation and Use • International application filed on Jan. 22, 2026 • Macrocyclic inhibitors of DYRK1A-B and methods of using them to treat disease Family 7 Macrocyclic DDR Target Inhibitors and Methods of their Preparation and Use • International application filed on Jan. 25, 2026 Family 8 Methods of Treating Cancer • Provisional application filed on Jan. 9, 2026 • Clinical methods of treating cancer using lead Wee1 inhibitor

GRAPHIC

29 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Securities Common Equivalents as of November 4, 2026 Preferred Stock (as converted) 15,596 Common Stock1 14,191,136 Pre-Funded Warrants 39,799,626 Purchase Warrants 45,844,103 Milestone Warrants 2,194,788 Options 1,107,804 Restricted Stock Units 65,438 Fully Diluted Equivalents 103,218,491 Aprea Therapeutics (NASDAQ: APRE) 1400,000,000 common shares authorized Cash and Equivalents of ~$37.8M as of September 30, 2026 $30.0M in gross proceeds raised in private placement that closed on March 31, 2026 Financial Summary and Capitalization

GRAPHIC

30 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Expected cash runway into Q1 2028 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR-1051: Q4 2026 Interim clinical data ✓ Q2 2027 Complete dose escalation enrollment • ATRN-119: October 2025 RP2D ✓ H2 2026 Potential collaborations on combinations Highly potent and selective design, potential best in class inhibitors • Diversified portfolio including WEE1 (APR-1051) and ATR (ATRN-119) inhibitors • Preliminary evidence of clinical activity including PRs with APR-1051 • Single agent and combination potential therapies Technology developed by pioneers in synthetic lethality • Management with strong drug development and commercial expertise • Focused on addressing unmet needs for patients with biomarker defined cancers Investment Highlights

GRAPHIC

31 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE)

Filing Exhibits & Attachments

5 documents

Keep reading